Certara (NASDAQ:CERT) Price Target Lowered to $8.00 at Barclays

Certara (NASDAQ:CERT) had its price objective dropped by investment analysts at Barclays from $13.00 to $8.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 16.84% from the company’s current price.

CERT has been the topic of several other reports. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Leerink Partners restated an “outperform” rating and set a $10.00 target price on shares of Certara in a research report on Thursday. Craig Hallum lowered Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research note on Friday. Rothschild & Co Redburn set a $10.00 price target on Certara in a research report on Friday, November 21st. Finally, TD Cowen reissued a “buy” rating on shares of Certara in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.10.

Certara Price Performance

CERT traded up $0.05 during trading on Friday, reaching $6.85. 468,662 shares of the company were exchanged, compared to its average volume of 2,530,113. Certara has a 12-month low of $6.04 and a 12-month high of $15.38. The company’s 50-day moving average is $8.40 and its two-hundred day moving average is $9.92. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 97.93 and a beta of 1.47.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a net margin of 2.62% and a return on equity of 5.18%. The company had revenue of $103.65 million for the quarter, compared to analysts’ expectations of $103.23 million. During the same period in the previous year, the firm earned $0.15 EPS. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Research analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Certara

Several hedge funds and other institutional investors have recently bought and sold shares of CERT. AQR Capital Management LLC purchased a new position in shares of Certara during the first quarter worth approximately $259,000. Goldman Sachs Group Inc. grew its holdings in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC lifted its stake in Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, Geneva Capital Management LLC boosted its position in Certara by 7.8% during the second quarter. Geneva Capital Management LLC now owns 6,114,895 shares of the company’s stock valued at $71,544,000 after buying an additional 443,206 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Key Headlines Impacting Certara

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Management highlights durable business trends: FY2025 revenue grew 9% to $418.8M and adjusted EBITDA rose 10%, while software revenue and bookings showed strength — signs of underlying demand and margin discipline. Certara FY2025 Results (Quiver)
• Positive Sentiment: New CEO Jon Resnick and a stated operational overhaul (including ~$10M cost avoidance) provide a catalyst for execution and potential improvement in commercial performance over 2026. New CEO & Operational Plan (Seeking Alpha)
• Neutral Sentiment: Management will be participating in investor conferences — this increases investor access and could provide incremental clarity on the strategic plan and guidance execution. Investor Conferences (GlobeNewswire)
• Neutral Sentiment: Full Q4 earnings materials and the earnings-call transcript are available for deeper read — useful for investors who want line-item detail on bookings, software vs services trends and non‑GAAP adjustments. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Q4 adjusted EPS of $0.09 missed consensus ($0.11) and GAAP adjusted diluted EPS declined vs prior year; this EPS weakness pressured sentiment. Q4 EPS Miss (Zacks)
• Negative Sentiment: FY2026 revenue guidance (0–4% growth; $418.8M–$435.6M) is below consensus revenue expectations (~$446.5M), creating downside risk to near-term estimates and investor sentiment. FY2026 Guidance (GlobeNewswire)
• Negative Sentiment: Craig‑Hallum downgraded CERT from Buy to Hold; while their $10 target still implies upside vs current levels, the rating cut signals some analysts are moving to a more cautious stance. Analyst Downgrade (Finviz)

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.